-
公开(公告)号:US20200246418A1
公开(公告)日:2020-08-06
申请号:US16828674
申请日:2020-03-24
IPC分类号: A61K38/095 , G01N33/49 , G01N15/10 , A61M27/00 , A61K45/06 , A61K9/00 , A61B5/145 , A61B5/0205 , A61K38/38
摘要: The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A patient identified as suffering from HRS-1 is tested to determine if the patient meets at least two out of three criteria, wherein the three criteria include a WBC 12 cells/4; HR>90 bpm; and any one of HCO3 20 breaths per minute. If the patient meets at least two of the criteria, he or she is administered terlipressin in an amount effective to produce a reduction in serum creatinine of at least 1.0 mg/dL.
-
公开(公告)号:US20200237856A1
公开(公告)日:2020-07-30
申请号:US16828681
申请日:2020-03-24
IPC分类号: A61K38/095 , G01N33/49 , G01N15/10 , A61M27/00 , A61K45/06 , A61K38/38 , A61K9/00 , A61B5/145 , A61B5/0205
摘要: The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A method of treating an adult patient with type 1 hepatorenal syndrome (HRS-1) may include assessing a baseline serum creatinine level prior to administration of terlipressin to the patient, initiating dosing of about 0.5 mg to about 1 mg of terlipressin to the patient every 6 hours by IV for 1-3 days, assessing a serum creatinine level in the patient at day 4±1 day from initiating dosing, administering a modified dosage of terlipressin based on a comparison of the assessed serum creatinine level at day 4±1 day and the baseline serum creatinine level, and continuing administration until 24 hours after two consecutive serum creatinine levels of ≤1.5 mg/dL at least 2 hours apart for a maximum of 14 days. The treatment may result in verified reversal of the HRS-1.
-
公开(公告)号:US20190328831A1
公开(公告)日:2019-10-31
申请号:US16411944
申请日:2019-05-14
IPC分类号: A61K38/095 , A61K45/06 , A61B5/0205 , A61B5/145 , A61K9/00 , A61K38/38 , G01N33/49 , A61M27/00 , G01N15/10
摘要: The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A patient identified as suffering from HRS-1 is tested to determine if the patient meets at least two out of three criteria, wherein the three criteria include a WBC 12 cells/4; HR>90 bpm; and any one of HCO3 20 breaths per minute. If the patient meets at least two of the criteria, he or she is administered terlipressin in an amount effective to produce a reduction in serum creatinine of at least 1.0 mg/dL.
-
公开(公告)号:US20190046705A1
公开(公告)日:2019-02-14
申请号:US16077276
申请日:2017-01-30
IPC分类号: A61M1/12 , A61B5/00 , A61B5/0215 , A61M1/10
摘要: Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.
-
公开(公告)号:US10201564B2
公开(公告)日:2019-02-12
申请号:US15170130
申请日:2016-06-01
摘要: The present invention provides a treatment of acute respiratory distress syndrome (ARDS) in children using dosing of nitric oxide at low concentrations, such as less than 10 ppm.
-
公开(公告)号:US20170232166A1
公开(公告)日:2017-08-17
申请号:US15418837
申请日:2017-01-30
CPC分类号: A61M1/122 , A61B5/02007 , A61B5/0215 , A61B5/029 , A61B5/0816 , A61B5/4842 , A61B5/4848 , A61B5/686 , A61B5/7275 , A61B8/0883 , A61M1/1086 , A61M2202/0275 , A61M2205/05 , A61M2205/3303 , A61M2205/3553 , A61M2230/04 , G16H20/40 , G16H50/30
摘要: Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.
-
公开(公告)号:US10667510B2
公开(公告)日:2020-06-02
申请号:US15066672
申请日:2016-03-10
发明人: Jim Potenziano , Douglas R. Hansell , Jeff Griebel , Eddie Costa , Lisa Cooper , David William Newman
摘要: Described are systems and methods for monitoring administration of nitric oxide (NO) to ex vivo fluids. Examples of such fluids include blood in extracorporeal membrane oxygenation (ECMO) circuits or perfusion fluids used for preserving ex vivo organs prior to transplanting in a recipient. The systems and methods described herein provide for administering nitric oxide to the fluid, monitoring nitric oxide or a nitric oxide marker in the fluid, and adjusting the nitric oxide administration.
-
公开(公告)号:US10188822B2
公开(公告)日:2019-01-29
申请号:US14657548
申请日:2015-03-13
IPC分类号: A61M16/12 , A61B5/055 , A61M16/00 , A61M16/06 , A61M16/08 , A61M16/16 , A61B5/087 , A61M16/10 , A61B5/00
摘要: The present invention relates to a device and method of delivering inhaled Nitric Oxide (iNO) to a patient situated in a Magnetic Resonance Imaging (MRI) suite.
-
公开(公告)号:US20170348502A1
公开(公告)日:2017-12-07
申请号:US15683290
申请日:2017-08-22
摘要: Described is an apparatus for monitoring nitic oxide delivery, wherein such apparatus comprises an indicator to inform a user of the apparatus when the flow of breathing gas rises above or falls below a predetermined level or range. Also described is a method of monitoring nitric oxide delivery, wherein the flow of breathing gas is measured and displayed. In some embodiments, an alert is provided when the flow of breathing gas rises above or falls below a predetermined level or range.
-
公开(公告)号:US20170215411A1
公开(公告)日:2017-08-03
申请号:US15493578
申请日:2017-04-21
发明人: Jim Potenziano , Douglas R. Hansell , Jeff Griebel , Eddie Costa , Lisa Cooper
CPC分类号: A01N1/0226 , A01N1/0247 , C12N5/0641
摘要: Described are systems and methods for monitoring administration of nitric oxide (NO) to ex vivo fluids. Examples of such fluids include blood in extracorporeal membrane oxygenation (ECMO) circuits or perfusion fluids used for preserving ex vivo organs prior to transplanting in a recipient. The systems and methods described herein provide for administering nitric oxide to the fluid, monitoring nitric oxide or a nitric oxide marker in the fluid, and adjusting the nitric oxide administration.
-
-
-
-
-
-
-
-
-